Unknown

Dataset Information

0

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.

ABSTRACT: We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

SUBMITTER: Dalla Costa G 

PROVIDER: S-EPMC7331489 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.

Dalla Costa Gloria G   Leocani Letizia L   Montalban Xavier X   Guerrero Ana Isabel AI   Sørensen Per Soelberg PS   Magyari Melinda M   Dobson Richard J B RJB   Cummins Nicholas N   Narayan Vaibhav A VA   Hotopf Matthew M   Comi Giancarlo G  

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 20200702 7

We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A tre  ...[more]

Similar Datasets

Unknown Real-time assessment of COVID-19 impact on global surgical case volumes.
| S-EPMC7273300 | biostudies-literature
Unknown Multiple sclerosis, rituximab, and COVID-19.
| S-EPMC8045943 | biostudies-literature
Unknown Real-time, interactive website for US-county level Covid-19 event risk assessment.
| S-EPMC7457615 | biostudies-literature
Unknown Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
| S-EPMC8689421 | biostudies-literature
Unknown Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study.
| S-EPMC7793465 | biostudies-literature
Transcriptomics Prevalence and Mechanisms of Mucus Plugging in COVID-19 Lung Disease
2022-08-03 | GSE210223 | GEO
Transcriptomics Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae
2022-02-01 | E-MTAB-10129 | biostudies-arrayexpress
Unknown Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC).
| S-EPMC8286899 | biostudies-literature
Unknown Review of the COVID-19 Risk in Multiple Sclerosis.
| S-EPMC8098748 | biostudies-literature
Unknown Characteristics of COVID-19 in patients with multiple sclerosis.
| S-EPMC8629769 | biostudies-literature